Clive Morris
Plus aucun poste en cours
Profil
Clive Morris worked as a Managing Director at CorpHQ, Inc. He was also an Investor Relations Contact at AstraZeneca PLC and President-Inivata at NeoGenomics, Inc. Morris was a Director at Inivata Ltd.
in 2022.
He holds a doctorate degree from The Royal College of Surgeons of England.
Anciens postes connus de Clive Morris
| Sociétés | Poste | Fin |
|---|---|---|
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Directeur Général | 18/06/2021 |
| NEOGENOMICS, INC. | Corporate Officer/Principal | 30/06/2022 |
| CorpHQ, Inc. | Corporate Officer/Principal | 06/08/2007 |
| ASTRAZENECA PLC | Public Communications Contact | - |
Formation de Clive Morris
| The Royal College of Surgeons of England | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| Entreprise privées | 2 |
|---|---|
| CorpHQ, Inc. | Communications |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
